Assessment of population susceptibility to upcoming seasonal influenza epidemic strain using interepidemic emerging influenza virus strains

Epidemiology and Infection

Volumn 147, Issue , 2019, Pages

  Chen, Lin Lei ^a   Wu, Wai Lan ^a   Chan, Wan Mui ^a   Fong, Carol H Y ^a   Ng, Anthony C K ^a   Ip, Jonathan D ^a   Lu, Lu ^a   Dissanayake, Thrimendra K ^a   Ding, Xixia ^b   Cai, Jian Piao ^a   Zhang, Anna J X ^a   Tam, Sidney ^c   Hung, Ivan F N ^a,d   Chan, Kwok Hung ^a,d,e   Yuen, Kwok Yung ^a,d,e,f   To, Kelvin K W ^a,d,e,f  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c QUEEN MARY HOSPITAL   (Hong Kong)

^d THE UNIVERSITY OF HONG KONG   (Hong Kong)

^e UNIVERSITY OF HONG KONG   (Hong Kong)

^f THE UNIVERSITY OF HONG KONG SHENZHEN HOSPITAL   (China)

Author keywords

Influenza; population susceptibility; respiratory tract infections; serology

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ADOLESCENT; ADULT; AGED; BLOOD; CHILD; DISEASE PREDISPOSITION; HONG KONG; HUMAN; IMMUNOLOGY; INFANT; INFLUENZA; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; DISEASE SUSCEPTIBILITY; HONG KONG; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA, HUMAN; MIDDLE AGED; YOUNG ADULT;

EID: 85072677631     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268819001717     Document Type: Article

References (38)

1. Iuliano AD et al. (2018) Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet 391, 1285-1300.
2. Collaborators GBDI (2019) Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017. Lancet Respiratory medicine 7, 69-89.
3. Beysard N et al. (2018) Impact of the 2014-2015 influenza season on the activity of an academic emergency department. Internal and Emergency Medicine 13, 251-256.
4. Poon CM et al. (2019) Management decision of hospital surge: assessing seasonal upsurge in inpatient medical bed occupancy rate among public acute hospitals in Hong Kong. QJM 112, 11-16.
5. Putri W et al. (2018) Economic burden of seasonal influenza in the United States. Vaccine 36, 3960-3966.
6. Caini S et al. (2018) Clinical characteristics and severity of influenza infections by virus type, subtype, and lineage: a systematic literature review. Influenza and Other Respiratory Viruses 12, 780-792.
7. Bedford T et al. (2015) Global circulation patterns of seasonal influenza viruses vary with antigenic drift. Nature 523, 217-220.
8. Skowronski DM et al. (2017) Age-related differences in influenza B infection by lineage in a community-based sentinel system, 2010-2011 to 2015-2016, Canada. Journal of Infectious Diseases 216, 697-702.
9. Budd AP et al. (2019) Birth cohort effects in influenza surveillance data: evidence that first influenza infection affects later influenza-associated illness. Journal of Infectious Diseases 220, 820-829.
10. Belongia EA et al. (2016) Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infectious Diseases 16, 942-951.
11. Monto AS et al. (2015) Antibody to influenza virus neuraminidase: an independent correlate of protection. Journal of Infectious Diseases 212, 1191-1199.
12. Zhu H et al. (2018) Low population serum microneutralization antibody titer against the predominating influenza A(H3N2) N121K virus during the severe influenza summer peak of Hong Kong in 2017. Emerging Microbes and Infection 7, 23.
13. To KK et al. (2010) Concurrent comparison of epidemiology, clinical presentation and outcome between adult patients suffering from the pandemic influenza A (H1N1) 2009 virus and the seasonal influenza A virus infection. Postgraduate Medical Journal 86, 515-521.
14. Zhang AJ et al. (2011) High incidence of severe influenza among individuals over 50 years of age. Clinical and Vaccine Immunology 18, 1918-1924.
15. Cheng VC et al. (2012) Two years after pandemic influenza A/2009/H1N1: what have we learned? Clinical Microbiology Reviews 25, 223-263.
16. Chan KH et al. (2011) Differences in antibody responses of individuals with natural infection and those vaccinated against pandemic H1N1 2009 influenza. Clinical and Vaccine Immunology 18, 867-873.
17. World Health Organization (2018) Recommended composition of influenza virus vaccines for use in the 2019 southern hemisphere influenza season. Available at https://www.who.int/influenza/vaccines/virus/recommendations/201809-recommendation.pdf (Accessed 20 December 2018).
18. Shu Y and McCauley J (2017) GISAID: Global initiative on sharing all influenza data - from vision to reality. Eurosurveillance 22, pii: 30494.
19. Deorowicz S, Debudaj-Grabysz A and Gudys A (2016) FAMSA: Fast and accurate multiple sequence alignment of huge protein families. Scientific Reports 6, 33964.
20. WHO Global Influenza Surveillance Network (2011) Manual for the Laboratory Diagnosis and Virological Surveillance of influenza. Geneva, Switzerland: WHO Global Influenza Surveillance Network.
21. Laurie KL et al. (2015) International laboratory comparison of influenza microneutralization assays for A(H1N1)pdm09, A(H3N2), and A(H5N1) influenza viruses by CONSISE. Clinical and Vaccine Immunology 22, 957-964.
22. Wang YD et al. (2009) Development and application of monoclonal antibodies-based antigen capture ELISA for detecting nucleocapsid protein of Influenza A virus. Guangdong Medical Journal 30, 703-705.
23. Hung IF et al. (2016) Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial. Lancet Infectious Diseases 16, 209-218.
24. To KK et al. (2012) High titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza. Clinical and Vaccine Immunology 19, 1012-1018.
25. Centre for Health Protection (2019) Local situation of influenza activity (as of Jan 9, 2019). Flu Express 16, 1-9.
26. European centre for Disease Prevention and Control (2019) Flu News Europe. Available at http://flunewseurope.org/ (Accessed 17 January 2019).
27. Centers for Disease Control and Prevention (2019) Weekly U.S. Influenza Surveillance Report, 2018-2019 Influenza Season Week 1 ending January 5, 2019. Available at https://www.cdc.gov/flu/weekly/#S1 (Accessed 17 January 2019).
28. Xie H et al. (2017) Differential effects of prior influenza exposures on H3N2 cross-reactivity of human postvaccination sera. Clinical Infectious Diseases 65, 259-267.
29. The Government of the Hong Kong Special Administration Region (2019) LCQ11: Seasonal influenza vaccination. Available at https://www.info.gov.hk/gia/general/201903/20/P2019032000606.htm (Accessed 11 May 2019).
30. European Centre for Disease Prevention and Control (2018) Influenza virus characterisation, Summary Europe, December 2018. Available at https://ecdc.europa.eu/en/publications-data/influenza-virus-characterisation-summary-europe-december-2018 (Accessed 12 February 2019).
31. European Centre for Disease Prevention and Control (2018) Influenza virus characterisation, Summary Europe, July 2018. Available at https://ecdc.europa.eu/en/publications-data/influenza-virus-characterisationsummary-europe-july-2018 (Accessed 27 January 2019).
32. Petrova VN and Russell CA (2018) The evolution of seasonal influenza viruses. Nature Reviews Microbiology 16, 60.
33. Skowronski DM et al. (2016) A perfect storm: impact of genomic variation and serial vaccination on low influenza vaccine effectiveness during the 2014-2015 season. Clinical Infectious Diseases 63, 21-32.
34. Smith DJ et al. (2004) Mapping the antigenic and genetic evolution of influenza virus. Science 305, 371-376.
35. Du X et al. (2017) Evolution-informed forecasting of seasonal influenza A (H3N2). Science Translational Medicine 9, pii: eaan5325.
36. Neher RA et al. (2016) Prediction, dynamics, and visualization of antigenic phenotypes of seasonal influenza viruses. Proceedings of the National Academy of Sciences 113, E1701-E1709.
37. World Health Organization (2019) Recommended composition of influenza virus vaccines for use in the 2019-2020 northern hemisphere influenza season. Available at https://www.who.int/influenza/vaccines/virus/recommendations/2019-20-north/en/ (Accessed 20 May 2019).
38. Zost SJ et al. (2017) Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proceedings of the National Academy of Sciences 114, 12578-12583.